Strand, Vibeke http://orcid.org/0000-0003-4978-4072
Gonçalves, Joao
Hickling, Timothy P.
Jones, Heather E.
Marshall, Lisa
Isaacs, John D.
Funding for this research was provided by:
Pfizer
Article History
First Online: 13 November 2019
Change Date: 26 February 2020
Change Type: Correction
Change Details: The article Immunogenicity of Biosimilars for Rheumatic Diseases, Plaque Psoriasis, and Inflammatory Bowel Disease: A Review from Clinical Trials and Regulatory Documents, written by Vibeke Strand, Joao Gon��alves, Timothy P. Hickling, Heather E. Jones, Lisa Marshall and John D. Isaacs, was originally published Online First without Open Access.
Compliance with Ethical Standards
:
: This review was sponsored by Pfizer.
: Professor Isaacs and work in the Isaacs’ laboratory are supported in part by NIHR Newcastle Biomedical Research Centre, based at Newcastle Hospitals NHS Foundation Trust and Newcastle University and by the Research into Inflammatory Arthritis Centre Versus Arthritis. V. Strand has received consulting fees or honoraria from AbbVie, Amgen, Asana, AstraZeneca, BMS, Boehringer Ingelheim, Celgene, Celltrion, EMD Serono, Genentech/Roche, GSK, Janssen, Kezar, Kypha, Lilly, Merck, Novartis, Pfizer, Regeneron, Samsung Bioepis, Sandoz, Sanofi, and UCB. J. Gonçalves has received speaker fees from Amgen, Biogen, Celltrion, Libbs, Novartis, Pfizer, Samsung Bioepis, and Sandoz. J. D. Isaacs has received speaker or consulting fees from AbbVie, Biogen, BMS, Celltrion, Eli Lilly, Gilead, Janssen, Merck, Merck Serono, Pfizer, and Roche. T. P. Hickling is an employee of Pfizer and may own company stock. H. E. Jones and L. Marshall were employees of Pfizer during the development of the manuscript and may own company stock.